Neurocrine CSO nets 3,587 shares in PRSU vest

NBIX’s Chief Scientific Officer had PRSUs vest into shares, with part withheld for taxes and no open-market stock sales.

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Scientific Officer Jude Onyia acquired 3,587 shares of Common Stock on September 11, 2026 from the vesting of previously granted performance restricted stock units (PRSUs) after a performance metric was certified as achieved.

On the same date, 1,936 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements related to that vesting at a reference price of $156.22 per share; the company states that no shares were sold, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Onyia Jude

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	3,587	$0.00	$0.00
Tax Withholding	Common Stock F2	1,936	$156.22	$302K

Holdings After Transaction: Common Stock — 22,647 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
2. F2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Key Figures

Shares acquired from PRSU vesting: 3,587 shares Shares withheld for tax: 1,936 shares Tax withholding reference price: $156.22 per share +2 more

5 metrics

Shares acquired from PRSU vesting 3,587 shares Common Stock acquired by Jude Onyia on September 11, 2026 via PRSU vesting

Shares withheld for tax 1,936 shares Common Stock withheld by the company to satisfy tax withholding on PRSU vesting

Tax withholding reference price $156.22 per share Price used for shares withheld to satisfy tax withholding requirements

PRSU vesting date September 11, 2026 Date on which achievement of a PRSU performance metric was certified

Shares used for tax liability or exercise price 1,936 shares Code F transaction reported as payment of tax liability by delivering or withholding securities

Key Terms

performance restricted stock units (PRSUs), vest, tax withholding requirements, withholding securities

4 terms

performance restricted stock units (PRSUs) financial

"previously granted performance restricted stock units (PRSUs) that vest upon the achievement"

vest financial

"PRSUs that vest upon the achievement of certain performance metrics"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

tax withholding requirements financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements"

withholding securities financial

"Payment of tax liability by delivering or withholding securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NBIX’s Chief Scientific Officer acquire in this Form 4?

Jude Onyia acquired 3,587 shares of Neurocrine Biosciences Common Stock on September 11, 2026 from the vesting of previously granted performance restricted stock units (PRSUs) after a performance metric was certified as achieved.

How many NBIX shares were withheld for taxes in this filing?

A total of 1,936 shares of Neurocrine Biosciences Common Stock were withheld by the company to satisfy tax withholding requirements upon vesting of PRSUs, at a reference price of $156.22 per share.

Were any NBIX shares sold on the market in this Form 4?

No. The company states that shares were withheld to satisfy tax withholding requirements on PRSU vesting and that no shares were sold in the market.

What triggered the PRSU vesting reported for NBIX?

Previously granted performance restricted stock units (PRSUs) vested for Jude Onyia after the achievement of certain performance metrics, with one metric certified as achieved on September 11, 2026.

Was a Rule 10b5-1 trading plan involved in this NBIX Form 4?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirming such a plan, and the footnotes describe PRSU vesting and tax withholding rather than trades under a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:07 PM Accepted by SEC EDGAR 09/15/2026 - 05:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Onyia Jude

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A(1)		3,587	A	$0	24,583	D
Common Stock	09/11/2026		F(2)		1,936	D	$156.22	22,647	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)